Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Hls Therapeutics Inc TSX: HLS-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

More stories below advertisement

HLS Therapeutics to Host Q3 2021 Financial Results Conference Call

Canada Newswire - Thu Oct 21, 2021

TORONTO , Oct. 21, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2021 financial results on Thursday, November 4, 2021 . The Company will hold a conference call that same day at 8:30 a.m. EDT to discuss its results. The call will be hosted by Mr. Gilbert Godin , Chief Executive Officer and Mr. Tim Hendrickson , Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast .

CONFERENCE ID:     

97175749



DATE:      

Thursday, November 4, 2021



TIME:       

8:30 a.m. EST



DIAL-IN NUMBER:  

1-888-664-6392 or 416-764-8659



WEBCAST LINK:   

https://produceredition.webcasts.com/starthere.jsp?ei=1503335&tp_key=b9fb30d53b  



TAPED REPLAY:    

1-888-390-0541 or 416-764-8677



REPLAY CODE:    

175749

The taped replay will be available for 14 days and the archived webcast will be available for 365 days.

A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com . Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.

ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/October2021/21/c4353.html

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2022.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies